| Website | aesrx.com |
| Category | BioTech |
| Phone | 617-965-2521 |
| info@aesrx.com | |
| Employees |
| TOTAL | $1.5M |
| FUNDING TOTAL | $1.5M |
| Venture Round, 7/11 | $1.5M |
| DEBT TOTAL | $1.91M |
| Debt, 5/11 | $1.38M |
| Debt, 9/12 | $525k |
AesRx (ǽs-r-ex) is a biopharmaceutical company dedicated to the development of two novel drugs, each of which targets an orphan disease. AesRx’s lead program, Aes-103, is a potential breakthrough in the treatment of sickle cell disease. Sickle cell disease is a recessive disorder of the hemoglobin which can cause red blood cells to deform into rigid sickle shapes that block capillaries and other small blood vessels. This blockage can lead to a wide range of serious, sometimes life-threatening, conditions including: chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, and cumulative damage to tissues and organs.
